scholarly article | Q13442814 |
P50 | author | Corrinne Segal | Q114574877 |
Simone Detre | Q114574878 | ||
Jack Cuzick | Q21005493 | ||
Anthony Howell | Q37828919 | ||
William G. Newman | Q38545164 | ||
Adam R Brentnall | Q40610182 | ||
Ivana Sestak | Q42801190 | ||
Mitch Dowsett | Q53099690 | ||
Elena López-Knowles | Q79297574 | ||
Trevor J. Powles | Q114415464 | ||
Helen J Byers | Q114574855 | ||
P2093 | author name string | Caroline Reuter | |
P2860 | cites work | An integrated map of genetic variation from 1,092 human genomes | Q22122153 |
Genome-wide association studies identify four ER negative-specific breast cancer risk loci | Q24622610 | ||
Genome-wide association study identifies novel breast cancer susceptibility loci | Q24645441 | ||
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk | Q27008356 | ||
Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Q29416989 | ||
Hereditary breast cancer: ever more pieces to the polygenic puzzle | Q33356511 | ||
Breast cancer risk assessment using genetic variants and risk factors in a Singapore Chinese population | Q33892384 | ||
Performance of common genetic variants in breast-cancer risk models | Q34064069 | ||
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). | Q34085748 | ||
Genome-wide association study identifies five new breast cancer susceptibility loci | Q34114293 | ||
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information | Q34267477 | ||
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer | Q34631785 | ||
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. | Q35082982 | ||
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population | Q35089479 | ||
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer | Q35755874 | ||
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Q35996692 | ||
The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions | Q36615665 | ||
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry | Q36619329 | ||
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial | Q36634556 | ||
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk | Q36720814 | ||
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers | Q36742577 | ||
Genome-wide association analysis identifies three new breast cancer susceptibility loci | Q36842233 | ||
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | Q36897003 | ||
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model | Q37172219 | ||
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. | Q37356243 | ||
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. | Q37369631 | ||
Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study | Q39006292 | ||
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. | Q42372951 | ||
Multilocus association mapping using variable-length Markov chains | Q42418605 | ||
Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK. | Q42587251 | ||
A concordance index for matched case-control studies with applications in cancer risk | Q44325877 | ||
Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention. | Q50654722 | ||
A breast cancer prediction model incorporating familial and personal risk factors. | Q52000310 | ||
A common coding variant in CASP8 is associated with breast cancer risk | Q57250674 | ||
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer | Q57251792 | ||
Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study | Q59288218 | ||
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually | Q69396132 | ||
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial | Q79803594 | ||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | single-nucleotide polymorphism | Q501128 |
tamoxifen | Q412178 | ||
P304 | page(s) | 743-750 | |
P577 | publication date | 2016-12-28 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. | |
P478 | volume | 35 |
Q93103805 | A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density |
Q91866775 | Assessment of breast cancer risk: which tools to use? |
Q52586080 | Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? |
Q89746441 | Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field |
Q52672618 | Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. |
Q92528444 | Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification |
Q38371172 | E-Science technologies in a workflow for personalized medicine using cancer screening as a case study |
Q55040393 | Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese. |
Q64080586 | Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer |
Q96302976 | Key steps for effective breast cancer prevention |
Q59349295 | Progress in preventive therapy for cancer: a reminiscence and personal viewpoint |
Q90744442 | Risk Models for Breast Cancer and Their Validation |
Q54950358 | Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. |
Q92993050 | Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts |
Q92755500 | Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management |
Q55385618 | ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. |
Search more.